Compare VABK & DERM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | VABK | DERM |
|---|---|---|
| Founded | 1998 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 235.8M | 190.3M |
| IPO Year | 2013 | 2021 |
| Metric | VABK | DERM |
|---|---|---|
| Price | $45.50 | $7.11 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $12.67 |
| AVG Volume (30 Days) | 7.2K | ★ 352.0K |
| Earning Date | 04-23-2026 | 05-13-2026 |
| Dividend Yield | ★ 3.39% | N/A |
| EPS Growth | 12.70 | ★ 34.72 |
| EPS | ★ 0.97 | N/A |
| Revenue | N/A | ★ $61,858,000.00 |
| Revenue This Year | N/A | $39.72 |
| Revenue Next Year | N/A | $63.24 |
| P/E Ratio | $47.23 | ★ N/A |
| Revenue Growth | N/A | ★ 10.20 |
| 52 Week Low | $36.60 | $4.31 |
| 52 Week High | $48.58 | $9.56 |
| Indicator | VABK | DERM |
|---|---|---|
| Relative Strength Index (RSI) | 69.87 | 57.80 |
| Support Level | $38.18 | $6.80 |
| Resistance Level | $48.18 | $7.33 |
| Average True Range (ATR) | 1.05 | 0.38 |
| MACD | 0.21 | 0.00 |
| Stochastic Oscillator | 100.00 | 70.16 |
Virginia National Bankshares Corp is a bank holding company engaged in commercial and retail banking. The bank offers a range of banking and related financial services, including checking accounts, negotiable order of withdrawal accounts, money market deposit accounts, certificates of deposit, individual retirement accounts, and other depository services. Its segments include the Bank, VNB Trust and Estate Services, and Masonry Capital. The Bank's commercial banking activities involve making loans, taking deposits, and offering related services to individuals, businesses, and charitable organizations.
Journey Medical Corp is a commercial-stage pharmaceutical company that focuses on the selling and marketing of U.S. Food and Drug Administration (FDA) approved prescription pharmaceutical products for the treatment of dermatological conditions. Its current product portfolio includes FDA-approved prescription drugs for dermatological conditions that are marketed in the U.S. The company views its operations and manages its business in one segment, which reflects products for the treatment of dermatological conditions. The dermatological segment derives revenues from the sale of branded and authorized general prescription products that treat certain dermatological conditions.